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Abstract
Background:  Mid-regional  proadrenomedullin  (MR-proADM)  is  a  novel  biomarker  with  potential
prognostic  utility  in  patients  with  community-acquired  pneumonia  (CAP).
Purpose:  To  evaluate  the  value  of  MR-proADM  levels  at  ICU  admission  for  further  severity  strat-
iﬁcation and  outcome  prediction,  and  its  kinetics  as  an  early  predictor  of  response  in  severe
CAP (SCAP).
Materials  and  methods:  Prospective,  single-center,  cohort  study  of  19  SCAP  patients  admitted
to the  ICU  within  12  h  after  the  ﬁrst  antibiotic  dose.
Results:  At  ICU  admission  median  MR-proADM  was  3.58  nmol/l  (IQR:  2.83--10.00).  No  signiﬁcant
association  was  found  between  its  serum  levels  at  admission  and  severity  assessed  by  SAPS  II
(Spearman’s  correlation  =  0.24,  p  =  0.31)  or  SOFA  score  (SOFA  <  10:  <3.45  nmol/l  vs.  SOFA  ≥  10:
3.90 nmol/l,  p  =  0.74).  Hospital  and  one-year  mortality  were  26%  and  32%,  respectively.  No
signiﬁcant difference  in  median  MR-proADM  serum  levels  was  found  between  survivors  and
non-survivors  and  its  accuracy  to  predict  hospital  mortality  was  bad  (aROC  0.53).  After  48  h
of antibiotic  therapy,  MR-proADM  decreased  in  all  but  5  patients  (median  −20%;  IQR  −56%  to
+0.1%). Its  kinetics  measured  by  the  percent  change  from  baseline  was  a  good  predictor  of
clinical response  (aROC  0.80).  The  best  discrimination  was  achieved  by  classifying  patients
Abbreviations: CAP, community-acquired pneumonia; ICU, Intensive Care Unit; COPD, Chronic Obstructive Pulmonary Disease; SAPS,
impliﬁed Acute Physiology Score; PIRO, Predisposition, Insult, Response, Organ failure; SOFA, Sepsis-related Organ Failure Assessment; PSI,
neumonia Severity Index; MR-proADM, mid-regional proadrenomedullin; SD, standard deviation; IQR, interquartile range; ROC, receiver
perating characteristics; aROC, area under the receiver operating characteristics curve.
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according  to  whether  MR-proADM  decreased  or  not  within  48  h.  No  decrease  in  MR-proADM
serum levels  signiﬁcantly  increased  the  chances  of  dying  independently  of  general  severity
(SAPS II-adjusted  OR  174;  95%  CI  2--15,422;  p  =  0.024).
Conclusions:  In  SCAP  patients,  a  decrease  in  MR-proADM  serum  levels  in  the  ﬁrst  48  h  after  ICU
admission  was  a  good  predictor  of  clinical  response  and  better  outcome.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
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Introduction
Community-acquired  pneumonia  (CAP)  remains  a  major
cause  of  morbidity,  mortality  and  healthcare  costs.1--3 In
9--16%  of  cases,  ICU  admission  is  needed,  due  to  severe
respiratory  failure,  severe  sepsis  or  septic  shock.4--6 In  these
patients,  mortality  is  high,  reaching  50%  in  those  patients
requiring  vasopressor  support.7 Inadequate  initial  antibiotic
therapy  is  a  poor  prognostic  factor.8--10
Severity  assessment  and  outcome  prediction  are  funda-
mental  in  the  management  of  CAP  patients,  both  to  allocate
the  most  appropriate  site  of  care  and  to  select  empiri-
cal  antibiotic  and  adjuvant  therapy.  Response  assessment
is  also  paramount.  Early  identiﬁcation  of  responders  and
non-responders  could  help  reduce  antibiotic  consumption  or
allow  earlier  rescue  antibiotic  therapy.  However,  there  is  no
standard  deﬁnition  for  clinical  response  in  severe  CAP.
Efforts  have  been  made  to  study  the  usefulness  of
biomarkers,  as  a  complement  to  clinical  judgment,  in  the
diagnosis,  severity  assessment,  treatment,  prognosis  and
follow-up  of  CAP.  In  recent  years,  promising  data  regarding
the  role  of  adrenomedullin  (ADM)  in  the  management  of  CAP
have  been  published.11--13 This  hormone,  a  peptide  with  52
aminoacids,  is  a  potent  vasodilator  agent  with  immune  mod-
ulating  and  metabolic  properties  and  bactericidal  activity
that  increases  in  sepsis.14 It  is  produced  by  multiple  tis-
sue  types  but,  unfortunately,  its  serum  levels  are  difﬁcult  to
measure,  since  it  is  rapidly  cleared  from  the  circulation.15--17
However,  the  more  stable  mid-region  fragment  of  proad-
renomedullin  (MR-proADM)  directly  reﬂects  levels  of  ADM.18
This  biomarker  may  be  as  good  as  validated  pneumonia-
speciﬁc  severity  scores  at  detecting  patients  with  severe
CAP  and  is  probably  better  than  other  biomarkers,  such
as  procalcitonin.11,12 MR-proADM  serum  level  correlate  well
with  mortality  (both  short  and  long  term)19 and  its  addi-
tion  to  clinical  scoring  systems  improves  their  discriminatory
power.11--13
The  purpose  of  our  study  was  to  evaluate  the  value  of  MR-
proADM  at  ICU  admission  for  further  severity  stratiﬁcation
and  outcome  prediction  and  to  assess  its  kinetics  as  an  early
marker  of  response  in  SCAP  patients.
Materials and methods
Study  designThis  was  a  single-center,  observational,  prospective  cohort
study  of  19  patients  with  severe  CAP  admitted  to  the  Inten-
sive  Care  Department  of  a  tertiary  care  university  hospital
c
u
t
Gn  Portugal  between  March  2012  and  January  2013.  The
tudy  was  approved  by  the  local  ethics  committee.  Writ-
en  informed  consent  was  obtained  from  every  patient  or
atient  representative  prior  to  inclusion  in  the  study.
CAP  was  diagnosed  when,  in  addition  to  suggestive  clini-
al  features  (e.g.  cough,  fever,  sputum  production,  pleuritic
hest  pain),  a demonstrable  inﬁltrate  by  chest  radiograph  or
T  scan  was  present.  Severe  CAP  was  deﬁned  according  to
he  Infectious  Diseases  Society  of  America/American  Tho-
acic  Society  criteria  (IDSA/ATS).20 In  order  to  be  included
nto  this  study,  patients  had  to  be  older  than  18  years  old
nd  have  MR-proADM  measured  within  12  h  after  the  ﬁrst
ntibiotic  dose.
ata  collection
he  following  parameters  were  registered  by  the  investi-
ators  in  a  speciﬁcally  created  database  at  the  moment
r  within  the  ﬁrst  24  h  of  ICU  admission:  age,  sex,  co-
orbidities,  corticosteroids  use,  existence  or  development
f  septic  shock  and/or  acute  respiratory  distress  syndrome
nd  empiric  antibiotic  therapy.  The  duration  of  mechanical
entilation,  length  of  hospital  and  ICU  stay  and  mortality
ICU,  hospital  and  1-year)  were  also  recorded.  Simpliﬁed
cute  Physiology  Score  (SAPS)  II21,  Sepsis-related  Organ  Fail-
re  Assessment  (SOFA)  score22,  Pneumonia  Severity  Index
PSI)6 and  PIRO-CAP23 were  calculated.
roadrenomedullin  determination
ithin  12  h  of  the  ﬁrst  antibiotic  dose,  a  blood  sample  was
ithdrawn  for  the  determination  of  MR-proADM  and  the  pro-
ess  was  repeated  48  h  later  except  for  one  patient.
MR-proADM  concentrations  (normal  <  0.52  nmol/l)  were
easured  at  the  Clinical  Biochemistry  Laboratory  of  Hospital
niversitario  Central  de  Asturias  (Oviedo,  Spain)  in  an  auto-
ated  Kryptor  analyzer,  using  TRACE  technology  (Kryptor;
RAHMS,  Hennigsdorf,  Germany),  without  any  pre-analytical
reatments  (i.e.,  extraction  or  derivatization).  Analytical
haracteristics  of  the  assay  and  reference  values  for  the
ealthy  adult  population  have  already  been  described.24
icrobiologic  evaluation
t  the  point  of  inclusion  into  the  study,  two  pairs  of  blood
ultures  were  collected.  Blood  cultures  were  processed
sing  an  automated  microbiology  growth  and  detection  sys-
em  (BACTEC).  If  there  was  bacterial  growth,  samples  were
ram  stained  and  subcultured.  A  bacteremic  episode  was
3 J.M.  Pereira  et  al.
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Table  1  Main  demographic  and  clinical  characteristics  of
the study  sample  (n  =  19).
n  (%)a
Age  (years)b 68  (64--82)
Male sex  11  (58)
SAPS II  scoreb 51  (41--61)
PSIb 5  (4--5)
PIRO-CAP
Mild-risk  6  (32)
High-risk  10  (52)
Very high-risk 3  (16)
SOFA scoreb 9  (8--12)
Co-morbidities  14  (74)
Diabetes  mellitus  7  (37)
COPD 6  (32)
Chronic  renal  failure  2  (11)
Alchool abuse  1  (5)
Congestive  heart  failure  1  (5)
Cancer 1  (5)
Microbiological  documentation  11  (58)
Microorganisms
Streptococcus  pneumoniae  6  (32)
Legionella  pneumophila  3  (16)
Haemophilus  inﬂuenza  1  (5)
Klebsiella  pneumoniae  1  (5)
Streptococcus  mitis  1  (5)
Secondary  bacteremia  5  (26)
Appropriate  antibiotic  therapy  11  (100)
Median time  to  ﬁrst  antibiotic  dose  (min)b 129  (78--160)
Duration  of  mechanical  ventilation  (days)b 8  (6--10)
Vasopressors  use  13  (68%)
ICU LOS  (days)b 11  (9--14)
Hospital  LOS  (days)b 17  (13--24)
Mortality
ICU 3  (16)
Hospital  5  (26)
28-day 5  (26)
One-year  6  (32)
SAPS: Simpliﬁed Acute Physiology Score; PSI: Pneumonia Sever-
ity Index; PIRO-CAP: Predisposition, Infection, Response, Organ
dysfunction-Community-acquired pneumonia; SOFA; Sepsis-
related Organ Failure Assessment; COPD: Chronic Obstructive
Pulmonary Disease; IDSA/ATS: Infectious Diseases Society of
America/American Thoracic Society; ICU: Intensive Care Unit;
LOS: Length of stay.
a Unless otherwise speciﬁed.
a
c
e
t10  
eﬁned  as  growth  of  a  typical  organism  for  CAP  in  at  least
ne  of  four  collected  blood  cultures.
Tracheal  aspirate  was  taken  from  every  patient  whenever
ossible  to  test  for  bacteria  according  to  standard  proce-
ures.  Representative  sputum  originating  from  the  lower
espiratory  tract  was  validated  by  the  criteria  of  >25  gra-
ulocytes  and  <10  epithelial  cells  per  low  power  ﬁeld  (total
agniﬁcation  ×  100).
Urine  samples  were  collected  and  tested  whenever
ossible  for  Legionella  pneumophila  and  Streptococcus
neumoniae  with  an  antigen  test.  Real-time  polymerase
hain  reaction  was  used  to  evaluate  the  presence  of  respi-
atory  virus  in  nasopharyngeal  swab  and  bronchoalveolar
avage  when  clinically  and  epidemiologically  indicated.
leural  ﬂuid  when  available  was  also  collected.
Identiﬁcation  of  microorganisms  and  susceptibility  test-
ng  was  performed  according  to  standard  methods.
tatistical  analysis
ategorical  variables  are  described  as  counts  and  per-
entages  and  continuous  variables  as  the  median  and
nterquartile  range  (IQR).  MR-proADM  kinetics  was  quan-
iﬁed  as  the  percent  change  from  baseline  accord-
ng  to:  (100*(MR-proADM[48  h]  −  MR-proADM[baseline])/MR-
roADM[baseline].  Spearman’s  correlations  were  used  to
uantify  the  association  between  MR-proADM  and  sever-
ty  scores.  Median  MD-proADM  levels  were  compared  across
ubgroups  using  the  Kruskal--Wallis  test.  The  area  under
he  receiver  operating  characteristics  (ROC)  curves  was
stimated  to  quantify  the  discrimination  of  MR-proADM
n  predicting  death  at  different  times.  The  association
etween  the  change  in  MR-proADM  and  death  was  assessed
y  odds  ratios  (OR)  estimated  by  logistic  regression,  adjus-
ing  for  severity  scores.
Statistical  analysis  was  performed  using  the  statistical
ackage  Stata  version  11.1  for  Windows  (StataCorp  LP,  Col-
ege  Station,  TX).
esults
emographic  and  clinical  characteristics  of  patients
he  median  age  of  the  overall  cohort  was  68  years
IQR  =  64--82),  58%  were  male  and  89.5%  of  the  cases  were
n  high-risk  PSI  classes  IV  and  V.  Median  SAPS  II  and  SOFA
core  were  55  (IQR  =  41--61)  and  9  (IQR  =  8--12),  respectively.
able  1  shows  global  baseline  characteristics  at  hospital
dmission.
SCAP  was  microbiologically  documented  in  58%  cases  and
.  pneumoniae  (n  =  6)  was  the  leading  pathogen  followed
y  L.  pneumophila  (n  =  3).  All  patients  received  antibiotic
herapy  concordant  with  IDSA/ATS  guidelines.20
roadrenomedullin  at  ICU  admission  and  severity
coresedian  MR-proADM  at  ICU  admission  was  3.58  nmol/l
IQR  =  2.83--10.00).  In  this  cohort,  no  signiﬁcant  associ-
tion  was  found  between  MR-proADM  serum  levels  at
s
p
sb Data presented as median (IQR).
dmission  and  severity  assessed  by  SAPS  II (Spearman’s
orrelation  =  0.24;  p  =  0.31)  (Fig.  1).  MR-proADM  serum  lev-
ls  were  higher  in  patients  with  SOFA  score  ≥10,  but
his  difference  did  not  reach  statistical  signiﬁcance  (SOFA
core  ≥  10:  3.90  nmol/l  vs.  SOFA  score  <  10:  3.45  nmol/l; = 0.74)  (Fig.  2).
As  for  SOFA  score,  patients  with  higher  pneumonia-
peciﬁc  severity  scores,  such  as  PSI  (class  III  and  IV:
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Figure  1  Serum  mid-regional  proadrenomedullin  levels
according  to  SAPS  II  score.
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Figure  4  Discrimination  of  mid-regional  proadrenomedullin
kinetics  in  the  ﬁrst  48  h  after  antibiotic  therapy,  as  measured
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dFigure  2  Serum  mid-regional  proadrenomedullin  levels
according  to  SOFA  score.
2.78  nmol/l  vs.  class  V:  3.74  nmol/l;  p  =  0.29)  and  PIRO  CAP
(mild  risk:  2.53  nmol/l  vs.  high  risk:  4.93  nmol/l  vs.  very  high
risk:  3.89;  p  =  0.23),  had  higher  MR-proADM  serum  levels  but
the  differences  were  not  statistically  signiﬁcant.
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Figure  3  Discrimination  of  serum  mid-regional  proadrenomedullin  
and one-year  mortality  (aROC  0.51;  95%  CI  0.25--0.78).y the  percent  decrease  from  baseline,  to  predict  hospital  mor-
ality (aROC  0.80;  95%  CI  0.47--1.00).
roadrenomedullin  at  ICU  admission  and  outcome
CU,  hospital  and  one-year  mortality  were  16%,  26%  and  32%,
espectively.  Median  MR-proADM  serum  levels  were  similar,
n  survivors  and  non-survivors  regarding  hospital  [survivors
.51  nmol/l  (IQR  =  2.60--13.00)  vs.  non-survivors  3.89  nmol/l
IQR  =  3.10--8.10);  p  =  0.89]  and  1-year  mortality  [survivors
.58  nmol/l  (IQR  =  2.40--13.00)  vs.  non-survivors  3.67  nmol/l
IQR  =  3.30--7.20);  p  =  1.0].  Receiver  operating  characteris-
ic  (ROC)  curve  analysis  showed  that  this  biomarker  at  ICU
dmission  had  a  bad  discriminatory  power  to  predict  hospi-
al  [aROC  0.53;  95%  conﬁdence  interval  (CI)  0.26--0.79]  and
-year  mortality  (aROC  0.51;  95%  CI  0.25--0.78)  (Fig.  3).
roadrenomedullin  kinetics  and  outcome
fter  48  h  of  antibiotic  therapy,  MR-proADM  serum  levels
ecreased  in  all  but  5  patients  (median  −20%;  IQR  =  −56%  to
0.1%).  MR-proADM  kinetics  measured  by  the  percent  change
rom  baseline  was  a  good  predictor  of  hospital  mortality
aROC  0.80;  95%  CI:  0.47--1.00)  (Fig.  4).
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levels  at  day  1  to  predict  hospital  (aROC  0.53;  95%  CI  0.26--0.79)
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The  best  discrimination  was  achieved  by  classifying
atients  according  to  MR-proADM  decreasing  (one  patient
ied  out  of  13)  or  not  (4  out  of  5  died)  within  48  h  of  antibi-
tic  therapy.  The  absence  of  reduction  in  this  biomarker
igniﬁcantly  increased  the  chances  of  dying  in  the  hospi-
al  independently  of  general  severity  [SAPS  II-adjusted  odds
atio  (OR)  174;  95%  CI:  2--15,422;  p  =  0.024].
iscussion
n  our  study  MR-proADM  at  ICU  admission  and  within  12  h
f  ﬁrst  antibiotic  dose  did  not  further  stratify  severity
n  patients  with  SCAP.  Furthermore,  serum  MR-proADM  at
his  stage  did  not  perform  well  as  a  predictor  of  both
hort-  (ICU  and  hospital)  and  long-term  (one-year)  mor-
ality.  Nevertheless,  MR-proADM  kinetics  in  the  ﬁrst  48  h
fter  antibiotic  therapy  was  a  good  tool  to  predict  hospital
ortality.
Considering  the  morbidity  and  mortality  associated  with
AP,  early  identiﬁcation  of  high  risk  patients  is  of  paramount
mportance.  Several  papers  demonstrate  an  association
etween  this  biomarker’s  serum  levels  and  severity  assessed
y  pneumonia  speciﬁc  scores  such  as  PSI.  Christ-Cain  et  al.
nd  Huang  DT  et  al.,11,12 reported  that  MR-proADM  levels
onsistently  rise  as  PSI  class  increases  (p  <  0.001).  In  49
atients  with  severe  sepsis/septic  shock  due  to  CAP  admit-
ed  to  the  ICU,  MR-proADM  consistently  rose  as  PSI  advanced
rom  II  to  V  (p  =  0.02).25 Yet,  our  results,  like  those  of  Akpinar
t  al.,26,  do  not  support  this  ﬁnding.  Although  patients  in
SI  class  V presented  higher  MR-proADM  serum  levels,  we
id  not  observe  any  signiﬁcant  difference  across  different
isk  classes  of  this  score.  Besides  the  sample  size,  differ-
nces  in  study  cohort,  namely  the  fact  that  only  severe
AP  patients  were  included,  may  explain  these  different
esults.
We  also  did  not  ﬁnd  a  signiﬁcant  association  with  sever-
ty  assessed  by  SAPS  II  or  SOFA  score.  In  contrast,  Marino
t  al.,27,  in  a  prospective  observational  study  in  patients
ith  suspected  sepsis  presenting  to  the  Emergency  Depart-
ent,  observed  a  moderate  association  of  MR-proADM  with
everity  of  disease  evaluated  by  APACHE  II  score  (r  =  0.46;
 <  0.001).  This  correlation  was  also  described  by  Travaglino
t  al.28 In  a  Swiss  study  with  101  critically  ill  patients,
R-proADM  levels  on  ICU  admission  exhibited  correlation
ith  APACHE  II  score  (r  =  0.42;  p  <  0.001)  and  SAPS  II  score
r  =  0.5;  p  <  0.001).29 These  differences  may  be  explained
y  the  different  types  of  population  studied.  Indeed,  our
tudy  was  the  ﬁrst  to  include  only  critically  ill  patients
ith  severe  sepsis  or  septic  shock,  a  signiﬁcant  propor-
ion  of  them  (68%)  needing  vasopressors  at  ICU  admission.
he  fact  that  MR-proADM  serum  levels  are  higher  in  these
roups  of  patients27,29 may  explain  the  lack  of  relation-
hip  between  this  biomarker  and  severity  scores  in  our
tudy.
In  the  emergency  department,  MR-proADM  seems  to  be
 very  good  prognostic  tool  to  predict  both  short  and
ong-term  outcome  in  patients  with  lower  respiratory  tract
nfections.19 However,  when  the  analysis  is  restricted  to  the
ost  severe  patients,  conﬂicting  results  have  been  pub-
ished.  According  to  Christ-Crain  study,29 the  prognostic
ccuracy  for  ICU  mortality  of  this  biomarker  on  admission,
s
a
d
sJ.M.  Pereira  et  al.
n  septic  critically  ill  patients,  is  good  (AUC  0.81),  simi-
ar  to  severity  scores  such  as  APACHE  II and  SAPS  II  score
nd  signiﬁcantly  better  than  other  biomarkers  such  as  C-
eactive  protein.  Huang’s  study12 showed  that,  within  PSI
lasses  IV/V  (n  =  546),  subjects  with  MR-proADM  higher  than
.45  nmol/l  had  a  higher  30-day  mortality  rate  (23%  vs.  9%;
 < 0.001).  In  a  subgroup  of  patients  (n  =  61)  with  high  risk  PSI
cores  (classes  IV  and  V),  Courtais  et  al.,30 showed  that,  in
nivariate  logistic  regression  analysis,  MR-proADM  levels  sig-
iﬁcantly  predicted  30-day  mortality  risk  (OR  4.68;  95%  CI:
.66--20.22)  with  an  aROC  curve  of  0.81  (95%  CI:  0.65--0.96).
evertheless,  only  24  of  these  patients  were  admitted  to  the
CU.
Like  other  studies,  we  observed  a  low  discriminatory
ower  of  MR-proADM  to  predict  hospital  and  one-year  mor-
ality.  Apkinar26 reported  that  this  biomarker  had  a  bad
iscriminatory  power  to  predict  4-  (AUC  0.505)  and  8-week
ortality  (AUC  0.513)  and  Marino  et  al.27 showed  a  poor  per-
ormance  to  predict  28  day-mortality  (AUC  0.60).  Despite
eing  slightly  better  than  previously  reported,  in  Subervi-
la’s  study  the  discriminatory  power  of  this  pro-hormone  to
redict  hospital  mortality  was  only  moderate  (AUC  0.72).25
Until  now,  there  have  been  no  published  data  regarding
he  value  of  MR-proADM  kinetics  in  the  management  of  SCAP
atients.  In  our  cohort,  we  found  that  after  48  h  of  antibiotic
herapy,  the  percent  change  from  baseline  was  a  good  pre-
ictor  of  hospital  mortality.  Indeed,  the  absence  of  decrease
n  serum  levels  was  an  independent  risk  factor  for  hospital
ortality.  Similar  ﬁndings  were  described  in  other  groups
f  patients.  For  instance,  in  febrile  patients  with  hemato-
ogic  malignancies,31 serum  MR-proADM  levels  dropped  in
atients  who  responded  to  therapy  whereas  in  patients  who
id  not  respond  there  was  no  signiﬁcant  change  between
nitial  (at  fever  onset)  and  follow-up  levels  (4--7  days  later).
urthermore,  septic  patients  admitted  to  the  emergency
epartment  with  high  plasma  ADM  (>70  pg/ml)  that  present
 decrease  in  serum  levels  in  the  ﬁrst  4  days  of  therapy
ave  a  higher  survival  rate  than  those  patients  whose  levels
emain  above  that  threshold  (100%  vs.  36%).27
The  fact  that  this  biomarker  was  collected  within  12  h
fter  the  ﬁrst  antibiotic  dose  in  patients  without  prior  antibi-
tic  use  and  that  all  patients  were  prospectively  enrolled  are
wo  of  the  strengths  of  this  study.  However,  some  limitations
lso  merit  consideration,  namely  the  fact  that  it  was  a  single
enter  study  and  that  the  generalizability  of  our  ﬁndings  is
imited  by  the  small  sample  size  (only  19  patients).  There-
ore,  these  results  should  be  validated  in  a  large  multicenter
tudy.
onclusions
e  concluded  that,  in  SCAP  patients,  MR-proADM  on  ICU
dmission  is  not  useful  for  further  severity  stratiﬁcation
nd  to  predict  both  short-  and  long-term  outcome.  How-
ver,  its  kinetics  in  the  ﬁrst  48  h  after  antibiotic  therapy  may
e  a  helpful  tool  to  assist  clinicians  in  identifying  patients
ith  a  better  clinical  outcome.  Moreover,  although  further
tudies  are  needed,  decreasing  levels  of  this  biomarker,  as
 sign  of  early  response  to  therapy,  may  lead  to  shorter
uration  of  antibiotic  therapy  and  play  a  role  in  antibiotic
tewardship.
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